675109-45-2

Usage

Uses

Used in Pharmaceutical Industry:
1H-Isoindol-1-one, 6-amino-2,3-dihydro(9CI) is used as a key intermediate in the synthesis of a novel potent glycoprotein IIb-IIIa (GP IIb-IIIa) receptor antagonist. GP IIb-IIIa receptor antagonists are important in the development of therapeutic agents for the treatment of various cardiovascular and thrombotic disorders. The unique isoindolone skeleton of 6-Amino-2,3-dihydroisoindol-1-one provides a promising structural basis for the design and development of new and effective GP IIb-IIIa receptor antagonists.

Upstream product

• 110568-64-4 6-nitroisoindolin-1-one 
• 3006-64-2 2-acetyl-2,3-dihydro-1H-isoindol-1-one 
• 110568-91-7 6-nitro-2-nitroso-isoindolin-1-one 
• 480-91-1 oxisoindole 
• 5415-18-9 2,3-Dihydro-2-nitroso-1H-isoindol-1-on 

Downstream Products

• 1184944-63-5 6-amino-2-(4-methoxyphenyl)isoindolin-1-one 
• 1037082-31-7 C₃₄H₄₀N₄O₈S 
• 1037082-40-8 C₃₆H₄₄N₄O₈S 
• 1036390-11-0 C₁₇H₁₅FN₂O₄ 
• 1036388-69-8 C₁₈H₁₈N₂O₅ 
• 675109-46-3 (3-oxo-2,3-dihydro-1H-isoindol-5-yl)carbamic Acid Tert-Butyl Ester 

Relevant academic research and scientific papers

[1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS

Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands

The present invention relates to compounds of formula I: in which R1 is a linear group or a five membered heterocycle optionally fused to a phenyl ring, R2 is a 5-membered heterocycle, R3 is chosen from a range of substituents, m is 0-3 and n is 0 or 1; the compounds are generally inverse agonists at GABA-A receptors containing the alpha 5 subunit and so are useful in methods of enhancing cognition in subjects with diminished cognition in diseases such as Alzheimer's Disease.